Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Flag link:
11 drugs granted FDA fast track designation in 2022
11 drugs granted FDA fast track designation in 2022
Beckers Hospital Review
FDA
fast track
Agios Pharmaceuticals
CTI BioPharma
Bristol Myers Squibb
Nobel Biocare
BioXcel Therapeutics
Mycovia Pharmaceuticals
Phathom Pharmaceuticals
Mitsubishi Tanabe Pharma
SIGA technologies
Alnylam Pharmaceuticals
Flag link:
FDA approves oral formulation of old ALS drug, giving patients new treatment option in sorely needed field
FDA approves oral formulation of old ALS drug, giving patients new treatment option in sorely needed field
Endpoints
Mitsubishi Tanabe Pharma
ALS
Radicava
FDA
Flag link:
Mitsubishi's Medicago readies for the second wave
Mitsubishi's Medicago readies for the second wave
EP Vantage
Mitsubishi Tanabe Pharma
Canada
Medicago
COVID-19
vaccines
Flag link:
Salix grabs ex-Asia rights to Mitsubishi Tanabe autoimmune drug
Salix grabs ex-Asia rights to Mitsubishi Tanabe autoimmune drug
Fierce Biotech
Salix
Mitsubishi Tanabe Pharma
amiselimod
Bausch Health
autoimmune disease
ulcerative colitis
Flag link:
Regeneron inks a $325M deal, selling Asian rights to a pain treatment
Regeneron inks a $325M deal, selling Asian rights to a pain treatment
Fierce Biotech
Regeneron
Mitsubishi Tanabe Pharma
musculoskeletal pain
fasinumab
Flag link:
On a crash course with Celgene? Biogen inks a $544M autoimmune drug deal
On a crash course with Celgene? Biogen inks a $544M autoimmune drug deal
Fierce Biotech
Celgene
Biogen
autoimmune disease
MT-1303
Mitsubishi Tanabe Pharma
Flag link:
China Biotech In Review: Fundings For China-Affiliated Drug Companies
China Biotech In Review: Fundings For China-Affiliated Drug Companies
Seeking Alpha
Shenogen Pharma
Zhongyuan Union Stem Cell Bioengineering
Sinopharm
ScinoPharm
Mitsubishi Tanabe Pharma
HengHeKangJian Pharmaceutica
Komtur Pharmaceuticals
Allium Medical
Zoetis
Flag link:
Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market
Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market
BioMedReports
Nuron Biotech
Mitsubishi Tanabe Pharma
HibTITER
vaccines
flu vaccines
Flag link: